Press Release Archives - Page 3 of 3 - IRIS CAPITAL INVESTMENT

25 May 21

BOOSTHEAT announces new funding in the form of an Equity Line with IRIS, up to €10 million, renewable twice

Paris, May 21, 2021 – BOOSTHEAT announces new funding in the form of an Equity Line with IRIS, up to €10 million, renewable twice DOWNLOAD Boostheat press release

22 Mar 21

Hybrigenics announces the implementation of an equity financing line.

Paris, March 22, 2021 – Hybrigenics has prioritized funding proposed by the company IRIS solution that offers very attractive financial conditions, including the absence of commission and complete flexibility with the ability to terminate without charge to print at any time. These funds will allow, like a SPAC1, to seize…

19 Jan 21

Theranexus implements a new equity line of an amount of up to €8.4 million in total over 12 months

Lyon, 18 January 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurologicaldiseases and pioneer in the development of drug candidates modulating the interaction between neurons and glialcells, presents an update on its activities and announces the strengthening of its financial visibilityfor the medium term.

22 Dec 20

Cerinnov Group announces the implementation of an equity line of an amount of €2 million

Cerinnov Group (code ISIN : FR0013178712 – mnémo : ALPCV), spécialiste de l’ingénierie robotique et des équipements industriels pour l’industrie de la céramique et du verre en France et à l’international, annonce ce jour la mise en place d’un financement en fonds propres d’un montant nominal maximum de 2…

28 Jul 20

Polyphor Strengthens financial flexibility with CHF 19.3 million equity-linked financing

Polyphor AG (SIX: POLN) today announced that it has entered into an equity-inked financing arrangement with the French company IRIS to raise a gross amount of up to CHF 19.3 million over the period of two years. IRIS will receive Polyphor shares to be created from the Company’s conditional…

09 Jul 20

Theranexus implements a Mandatory Convertible Bond facility

THERANEXUS ANNOUNCES ITS CASH POSITION AS OF 30 JUNE 2020 ANDIMPLEMENTATION OF A MANDATORY CONVERTIBLE BOND FACILITY • Pro forma cash of €13.3 M at 30 June 2020• Implementation of financing for a maximum total of €4.2 million over 12 months through the issuance of warrants to subscribe mandatory convertible…

29 Apr 20

Bone Therapeutics secures EUR 11 million financing

Gosselies, Belgium, 29 April 2020, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that it secured EUR 11.0 million financing. The financing will be used to advance both of its key…

08 Apr 20

Santhera Enters into Equity-linked Financing to Provide up to CHF 12 million with the Option to Increase to up to CHF 24 million

Santhera Enters into Equity-linked Financing to Provide up to CHF 12 million with the Option to Increase to up to CHF 24 million Pratteln, Switzerland, April 8, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that it has entered into an equity-linked financing arrangement with IRIS (France) in the initial gross…

05 Dec 19

DMS enters into a EUR 4 million Mandatory Convertible Bond facility, convertible into DMS or Hybrigenics shares

Mise en place d’un financement d’un montant maximum de 4 M€ par bons d’émission d’obligations remboursables en numéraire et/ou en actions DMS ou Hybrigenics.

Press Release

Links